Compare Abbott Laboratories (ABT) vs Global E Online Ltd (GLBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Global E Online Ltd — how do they compare? Abbott Laboratories trades at $109.36 (market cap $187.95B), while Global E Online Ltd trades at $42.45 (market cap $6.90B). The key difference: Abbott Laboratories is far larger — about 27.2× Global E Online Ltd's market cap, and Abbott Laboratories pays a 2.32% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals.
| ABT | GLBE | |
|---|---|---|
Market Cap | $187.95B | $6.90B |
Sector | Health | Technology |
52-Week High | $136.62 | $42.32 |
52-Week Low | $82.57 | $27.54 |
Enterprise Value | $214.96B | $6.37B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
GLBE trades at $42.32, up 3.17% in the past 24 hours, near its 52-week high. The stock shows bullish technical signals with strong moving average support, though RSI indicates overbought conditions. Recent earnings have been mixed, with a beat in Q4 2025 but a miss in Q1 2026. The company reported 2025 revenue of $962.20 million and net income of $68.27 million, with profitability improving into 2026. Key developments include the acquisition of Passport to enhance logistics capabilities and a $500 million share repurchase program authorized by the board.
GLBE presents a growth opportunity with robust analyst support—100% buy ratings and a consensus price target of $44.75, suggesting upside potential. However, risks include high valuation multiples like a P/E of 61.33, competitive pressures in e-commerce enablement, and insider selling by the CEO. Investors should weigh the strong growth trajectory against premium valuation and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →
